In addition, 81.58% of the primary tumors in T1/T2 stages had weak staining for MAL, whereas of 12 tumor cases in T3/T4 stages, only 1 (8.33%) had weak reactions for MAL. The gene discussed is MAL; the disease is neoplasm.